EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Semaglutide for Treating Paediatric Craniopharyngioma‐Related Obesity: A Multicentre Case Series

Joanne Dornberger, Pascal Barat, Karine Aouchiche, Kevin Perge, Carine Villanueva, Sarah Castets, Natacha Bouhours-Nouet, Aurelie Donzeau, Lucie Levaillant, Cecile Teinturier, Rachel Reynaud, Ahlam Azar-Kolakez und 3 weitere

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11828-11838

DOI: 10.1111/dom.71403 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 28.09.2026. Verfasst von Joanne Dornberger und 14 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine, Bone Diseases and Genetics Unit, Children's Hospital, Toulouse University Hospital, Toulouse, France. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Craniopharyngioma, Pituitary Neoplasms, Pediatric Obesity. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Obesity is a complication of childhood craniopharyngioma that remains difficult to treat. We investigated whether semaglutide was associated with a decrease in BMI among adolescents with craniopharyngioma‐related obesity. Material and Methods This multicentre retrospective study included 20 patients < 18 years old with craniopharyngioma and obesity (BMI > 2 WHO Z ‐score) from 2019 to 2024 (source population: 139 children with craniopharyngioma, including 36 children with obesity). They received off‐label semaglutide with dose titration (0.25–2 mg/week), tailored to tolerance and clinical response. The primary outcome was the within‐patient comparison of BMI change from −12 months to treatment initiation and from initiation to +12 months.

Results

At semaglutide initiation, patients were 14.0 ± 3.9 years old, the interval since craniopharyngioma diagnosis was 6.3 ± 4.7 years, and BMI was 33.4 ± 3.9 kg/m 2 (3.2 ± 0.7 Z ‐score). Tumour treatment was surgery alone (8/20), surgery and proton therapy (11/20), or proton therapy alone (1/20). All patients had growth hormone and TSH deficiency; 19/20 had ACTH and AVP deficiency. In the year before treatment, patients gained 3.5 ± 4.4 kg/m 2 in BMI and 0.6 ± 1.6 in BMI Z ‐score; after 1 year of semaglutide therapy, they lost 2.5 ± 3.9 kg/m 2 in BMI and 0.5 ± 0.5 in BMI Z ‐score (paired comparisons, p < 0.001 and p = 0.004, respectively). During treatment, BMI decreased by 10% or more in 40% of patients (95% CI: 19%–64%). Gastrointestinal side effects occurred in 30% of patients but were mild. No cases of treatment discontinuation, pituitary insufficiency decompensation or tumour recurrence were observed.

Conclusions

Semaglutide was associated with reversal of weight gain among adolescents with craniopharyngioma‐related obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesCraniopharyngiomaPituitary NeoplasmsPediatric ObesityHumansSemaglutideFemaleMaleAdolescentRetrospective StudiesChildBody Mass IndexTreatment Outcome

Stichwörter der Autor:innen

childrencraniopharyngiomaglucagon‐like peptide‐1 receptor agonisthypothalamic obesitysemaglutide

Substanzen

SemaglutideGlucagon-Like Peptides

Autor:innen und Institutionen

  • Endocrine, Bone Diseases and Genetics Unit, Children's Hospital, Toulouse University Hospital, Toulouse, France.
  • Department of Pediatric Endocrinology, CHU Bordeaux, Bordeaux, France.
  • Reference Center for Rare Obesity, CHU Bordeaux, Bordeaux, France.
  • Department of Pediatric Endocrinology, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
  • Reference Center for Rare Pituitary Diseases, Marseille, France.
  • Department of Pediatric Endocrinology, Civil Hospices of Lyon, Lyon, France.

ORCID-Profile: Regis Coutant

Zitieren

APA

Dornberger, J., Barat, P., Aouchiche, K., Perge, K., Villanueva, C., Castets, S., Bouhours-Nouet, N., Donzeau, A., Levaillant, L., Teinturier, C., Reynaud, R., Azar-Kolakez, A., Martinerie, L., Kariyawasam, D., & Coutant, R. (2026). Semaglutide for Treating Paediatric Craniopharyngioma‐Related Obesity: A Multicentre Case Series. Diabetes, Obesity and Metabolism, 28(12), 11828-11838. https://doi.org/10.1111/dom.71403

Vancouver

Dornberger J, Barat P, Aouchiche K, Perge K, Villanueva C, Castets S, et al. Semaglutide for Treating Paediatric Craniopharyngioma‐Related Obesity: A Multicentre Case Series. Diabetes, Obesity and Metabolism. 2026;28(12):11828-11838. doi:10.1111/dom.71403

BibTeX
@article{Dornberger2026,
  author = {Dornberger, Joanne and Barat, Pascal and Aouchiche, Karine and Perge, Kevin and Villanueva, Carine and Castets, Sarah and Bouhours-Nouet, Natacha and Donzeau, Aurelie and Levaillant, Lucie and Teinturier, Cecile and Reynaud, Rachel and Azar-Kolakez, Ahlam and Martinerie, Laetitia and Kariyawasam, Dulanjalee and Coutant, Regis},
  title = {Semaglutide for Treating Paediatric Craniopharyngioma‐Related Obesity: A Multicentre Case Series},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11828--11838},
  doi = {10.1111/dom.71403}
}
Kostenlos starten →